Delivery Order SPE2DB22D2206-SPE2DB24FKD63

Award Date 9/5/24
Potential Completion Date 9/26/24
Potential Value $14K
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This is a firm fixed price delivery order contract awarded by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a subsidiary of the global pharmaceutical distributor Amerisourcebergen Corporation. The contract, valued at $9,660.94, is for the delivery of the specialty medication INQOVI 35 MG-100 MG TABLET with a completion date of March 20, 2024. The contract does not have a set-aside designation. Amerisourcebergen Drug Corp, through its Corporate Office division, serves as...
This is a federal contract award to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, by the Defense Logistics Agency (DLA). The $5,119.36 firm fixed-price delivery order contract is for the supply of INQOVI 35 MG-100 MG tablets. The contract has an ultimate completion date of April 22, 2025. This award is part of a larger Indefinite Delivery Contract (IDC) valued at $999,999,999 that AmerisourceBergen holds with the DLA Troop Support Medical, which serves as a primary vehicle for...
This is a $5,119.36 firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The award is for the supply of INQOVI 35 MG-100 MG TABLET, a pharmaceutical product, and does not have a set-aside designation. AmerisourceBergen holds a $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves as a primary vehicle for providing a...
This is a delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $5,119.36 firm fixed-price contract is for the delivery of INQOVI 35 MG-100 MG TABLET UU 5S, a pharmaceutical product. The contract has an ultimate completion date of April 1, 2025. AmerisourceBergen is the prime contractor, with no major subcontractors mentioned. The award is not associated with a specific set-aside...
The U.S. Defense Logistics Agency (DLA) awarded a firm fixed price delivery order to Amerisourcebergen Drug Corp, a subsidiary of Amerisourcebergen Corporation, to provide INQOVI 35 MG-100 MG tablets. The $4,830.47 contract has a completion date of March 25, 2024. Amerisourcebergen Drug Corp holds an Indefinite Delivery Contract (IDC) with DLA, valued up to $999,999,999.00 through December 31, 2025, which serves as the primary vehicle for the company to deliver pharmaceuticals and medical...
This is a delivery order issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, for the delivery of INQOVI 35 MG-100 MG tablets. The $5,119.36 firm fixed-price contract has a period of performance through March 7, 2025. AmerisourceBergen holds a larger $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves as a primary vehicle for providing a comprehensive range of pharmaceutical products and...
This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corporation for the supply of INQOVI 35 MG-100 MG TABLET. The contract has a firm fixed price of $4,830.47 and an ultimate completion date of August 13, 2024. The contract does not have a set-aside designation. AmerisourceBergen, a major pharmaceutical distributor, will be the prime contractor responsible for providing the prescribed medication to support federal healthcare programs,...
This is a delivery order awarded by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $4,830.47 firm-fixed-price contract is for the delivery of INQOVI 35 MG-100 MG tablets, a pharmaceutical product, with a performance period through April 15, 2024. The award is not designated as a set-aside contract. Amerisourcebergen holds a $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support...
The U.S. Defense Logistics Agency (DLA) Troop Support Medical awarded a firm fixed price delivery order contract to AmerisourceBergen Drug Corp, a subsidiary of AmerisourceBergen Corporation, to provide 4564134395! INQOVI 35 MG-100 MG TABLET UU 5S. The award, valued at $4,830.47, has an ultimate completion date of April 22, 2024. AmerisourceBergen Drug Corp, through its Corporate Office division, specializes in supplying pharmaceuticals, medical supplies, and related distribution services to...
This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp. The contract is for the supply of INQOVI 35 MG-100 MG tablets, a pharmaceutical product. The contract has a ceiling value of $9,660.94 and an ultimate completion date of October 7, 2024. The contract is a firm fixed-price, delivery order type with no set-aside designation. AmerisourceBergen Drug Corp is a major supplier of pharmaceutical products and medical supplies to the U.S....
  • SPE2DB22D2206
    Indefinite Delivery Contract
  • SPE2DB22D2206-SPE2DB24FKD63
    Delivery Order

This is a delivery order awarded to AmerisourceBergen Drug Corp's Corporate Office Division by the Defense Logistics Agency (DLA) for the supply of pharmaceutical products, specifically the drug INQOVI 35 MG-100 MG TABLET. The contract has a firm-fixed price of $14,491.41 and a completion date of September 26, 2024. This award is part of a larger Indefinite Delivery Contract (IDC) between AmerisourceBergen and the DLA Troop Support Medical, valued at up to $999,999,999 through December 2025, which serves as a primary vehicle for providing a comprehensive range of medical commodities to support military treatment programs and facilities worldwide.

Generated 12/5/24, 9:46 AM